Human papillomavirus infection (HPV infection) is caused by a DNA virus from the Papillomaviridae family. Many HPV infections cause no symptoms and 90% resolve spontaneously within two years. Available HPV vaccines protect against either two, four, or nine types of HPV. All HPV vaccines protect against at least HPV types 16 和 18, which cause the greatest risk of cervical cancer. It is estimated that HPV vaccines may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, 40% of vulvar cancer, and show more than 90% efficacy in preventing HPV-positive oropharyngeal cancers. 据Gen咨询公司称, the global human papillomavirus market is set to achieve an incremental growth of USD 3 十亿, 复合年增长率几乎达到 6.3% 在预测期内 2022-2028.

该报告提供了有关当前全球市场情况的深入分析和见解, latest trends and drivers into global human papillomavirus market. 它提供了对市场规模等各种细节的独家见解, 主要趋势, 竞争格局, 增长率和细分市场. This study also provides an analysis of the impact of the COVID-19 crisis on the human papillomavirus industry.

该行业报告提供了全球市场的市场估计和预测, 其次是类型的详细分析, dosage, 应用, age, 最终用户, 和地区. The global market for human papillomavirus can be segmented by type: bivalent HPV vaccine (2vHPV), quadrivalent HPV vaccine (4vHPV), 9-valent HPV vaccine (9vHPV). Human papillomavirus market is further segmented by dosage: 2 dose, 3 dose. 根据应用, the human papillomavirus market is segmented into: HPV-attributable cancer, genital warts. On the basis of age, the human papillomavirus market also can be divided into: under 15 年, 15 到 45 年. Human papillomavirus market by end user is categorized into: community clinics, doctor’s office, health departments, 医院, school-based health centers, 其他的. The human papillomavirus market by region can be segmented into: 亚太地区, 欧洲, 北美, 世界其他地区 (排).

按类型:
– bivalent HPV vaccine (2vHPV)
– quadrivalent HPV vaccine (4vHPV)
– 9-valent HPV vaccine (9vHPV)

By dosage:
– 2 dose
– 3 dose

按申请:
– HPV-attributable cancer
– genital warts

By age:
– under 15 年
– 15 到 45 年

按最终用户:
– community clinics
– doctor’s office
– health departments
– 医院
– school-based health centers
– 其他的

按地区:
– 亚太地区
– 欧洲
– 北美
– 世界其他地区 (排)

The market research report covers the analysis of key stake holders of the global human papillomavirus market. Some of the leading players profiled in the report include Beijing Health Guard Biotechnology Inc., Beijing Wantai Biopharmaceutical Co., 有限公司, BioLeaders Corporation, 葛兰素史克公司, Inovio Pharmaceuticals, 公司, 默克 & 公司。, 公司, R-Pharm Group, 赛诺菲公司, Serum Institute of India Pvt. 有限公司, Vaccitech plc, Walvax Biotechnology Co., 有限公司, 除其他外.
*索取免费样品以获得完整的公司列表

历史 & 预测期
本研究报告对各个细分市场进行了分析 2018 到 2028 考虑到 2021 为基准年.

报告范围
– To analyze and forecast the market size of the global human papillomavirus market.
– To classify and forecast the global human papillomavirus market based on type, dosage, 应用, age, 最终用户, 地区.
– To identify drivers and challenges for the global human papillomavirus market.
– 检查合并等竞争性发展 & 收购, 协议, 合作与伙伴关系, ETC。, in the global human papillomavirus market.
– To identify and analyze the profile of leading players operating in the global human papillomavirus market.

为什么选择这份报告
– Gain a reliable outlook of the global human papillomavirus market forecasts from 2022 到 2028 跨场景.
– 确定投资的增长领域.
– 通过公司简介和市场数据领先于竞争对手.
– Excel 格式的跨场景分析易用性的市场预估.
– 三个月的战略咨询和研究支持.
– 为单用户许可证提供打印验证.